Search
Dorzolamide
go.drugbank.com/drugs/DB00869ApprovedInvestigational[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. … [A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]
Mixtures: DORZOLAMIDE E TIMOLOLO EG, DORZOLAMIDE E TIMOLOLO EGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesIcosapent
go.drugbank.com/drugs/DB00159ApprovedInvestigationalNutraceutical-2 and prostaglandin-2 families. … Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families.
Synonyms: (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate, (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acidMixtures: Herbs of Gold Salmon Oil 1000 mg, Live-well™ Toco-E CapsuleSolifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigational[L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Mixtures: VESOMNİ 6 MG/0.4 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 ADET, Vesomni 6 mg/0,4 mg Tabletten mit veränderter WirkstofffreisetzungCategories: Heterocyclic Compounds, 2-Ring, Drugs Used in Benign Prostatic HypertrophyApremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigationalIt belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. … Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases.
Synonyms: N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamideMixtures: OTEZLA (10 MG 20 MG 30 MG), OTEZLA (10 MG 20 MG 30 MG)Pantothenic acid
go.drugbank.com/drugs/DB01783ApprovedInvestigationalNutraceuticalVet approvedFor many animals, pantothenic acid is an essential nutrient as it is required to synthesize coenzyme-A (CoA), as well as to synthesize and metabolize proteins, carbohydrates, and fats. … Williams in 1919.
Mixtures: Stress B With 1000 Mg Vitamin C, B Plus C 300 mgProducts: Pantothenic Acid 500 mg, Pantothenic Acid 100 Mg TabletsAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc.
Products: STRENSİQ 40 MG/1.0 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 28 MG/0.7 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADETPropafenone
go.drugbank.com/drugs/DB01182ApprovedInvestigationalAn antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: 2-(2'-hydroxy-3'-propylaminopropoxy)-ω-phenylpropiophenone, 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanoneOmega-3-acid ethyl esters
go.drugbank.com/drugs/DB09539ApprovedInvestigationaltriglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia[FDA Label][A176687]. … Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849].
Mixtures: Mi-Omega NF, ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICIProducts: OMACOR 1000 mg Weichkapseln, Zodin 1000 mg - WeichkapselnEmicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.
Products: HEMLIBRA® 150 MG/ML SOLUCIÓN INYECTABLE, HEMLİBRA 105 MG/ 0.7 ML S.C. ENJEKSİYONLUK ÇÖZELTİ, 1 ADETMirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigationalIt inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases. … [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with
Categories: Interleukin-23 AntagonistProducts: Misuvya 100 mg/1 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 2 ADET, Misuvya 100 mg/1 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 6 ADET